The development of biosimilars, which are highly similar to approved biologics, offers a cost-effective solution to increasing healthcare expenses while expanding access to critical therapies. This study aims to investigate the regulatory and manufacturing challenges in biosimilar development and propose actionable strategies to mitigate these barriers. A systematic review of regulatory guidelines and peer-reviewed literature was conducted, focusing on global regulatory frameworks, analytical methods, and manufacturing complexities. Statistical analyses were applied to assess variations in regulatory requirements and their impact on biosimilar development costs and timelines.

The results revealed significant disparities between regulatory frameworks, notably between the FDA and EMA, with the latter requiring additional clinical trials, leading to higher development costs and delayed global market access. Manufacturing challenges, particularly process variability, were identified as major contributors to regulatory rejection rates. Statistical analysis indicated a strong correlation between manufacturing process inconsistencies and product rejections (p < 0.01). The economic evaluation highlighted that regulatory requirements accounted for approximately 40% of the total development costs, emphasizing the need for harmonized guidelines and cost-effective solutions.